ultivue.com
Open in
urlscan Pro
52.54.14.105
Public Scan
Submitted URL: http://ultivue.com/
Effective URL: https://ultivue.com/
Submission: On December 09 via manual from US — Scanned from DE
Effective URL: https://ultivue.com/
Submission: On December 09 via manual from US — Scanned from DE
Form analysis 3 forms found in the DOM
GET https://ultivue.com/
<form method="get" id="searchform" action="https://ultivue.com/">
<i class="icon_search icon-search-fine"></i>
<a href="#" class="icon_close"><i class="icon-cancel-fine"></i></a>
<input type="text" class="field" name="s" placeholder="Enter your search">
<input type="submit" class="display-none" value="">
</form>POST /#gf_3
<form method="post" enctype="multipart/form-data" target="gform_ajax_frame_3" id="gform_3" class="gf_simple_horizontal gform_legacy_markup" action="/#gf_3">
<input type="hidden" class="gforms-pum" value="{"closepopup":false,"closedelay":0,"openpopup":false,"openpopup_id":0}">
<div class="gform_body gform-body">
<ul id="gform_fields_3" class="gform_fields top_label form_sublabel_below description_below">
<li id="field_3_1" class="gfield gf_inline sign-up-input gfield_contains_required field_sublabel_below field_description_below gfield_visibility_visible"><label class="gfield_label screen-reader-text" for="input_3_1">Your email address<span
class="gfield_required"><span class="gfield_required gfield_required_asterisk">*</span></span></label>
<div class="ginput_container ginput_container_email">
<input name="input_1" id="input_3_1" type="text" value="" class="medium" placeholder="Your email address" aria-required="true" aria-invalid="false">
</div>
</li>
</ul>
</div>
<div class="gform_footer top_label"> <input type="submit" id="gform_submit_button_3" class="gform_button button" value="Sign Me Up" onclick="if(window["gf_submitting_3"]){return false;} window["gf_submitting_3"]=true; "
onkeypress="if( event.keyCode == 13 ){ if(window["gf_submitting_3"]){return false;} window["gf_submitting_3"]=true; jQuery("#gform_3").trigger("submit",[true]); }"> <input type="hidden" name="gform_ajax"
value="form_id=3&title=&description=&tabindex=0">
<input type="hidden" class="gform_hidden" name="is_submit_3" value="1">
<input type="hidden" class="gform_hidden" name="gform_submit" value="3">
<input type="hidden" class="gform_hidden" name="gform_unique_id" value="">
<input type="hidden" class="gform_hidden" name="state_3" value="WyJbXSIsIjcyZWU4M2UxMjk3NTUwNTZjMmI4MDI3ZmMyMTAzZGUwIl0=">
<input type="hidden" class="gform_hidden" name="gform_target_page_number_3" id="gform_target_page_number_3" value="0">
<input type="hidden" class="gform_hidden" name="gform_source_page_number_3" id="gform_source_page_number_3" value="1">
<input type="hidden" name="gform_field_values" value="">
</div>
</form>GET https://ultivue.com/
<form id="side-form" method="get" action="https://ultivue.com/"><input type="text" class="field" name="s" placeholder="Enter your search"><input type="submit" class="display-none"
value=""><a class="submit" href="#"><i class="icon-search-fine"></i></a></form>Text Content
This website stores cookies on your computer. These cookies are used to collect information about how you interact with our website and allow us to remember you. We use this information in order to improve and customize your browsing experience and for analytics and metrics about our visitors both on this website and other media. To find out more about the cookies we use, see our Privacy Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked. Accept Decline * Products * Workflow * Panels * Image Analysis * Services & Programs * Staining & Image Analysis * Biomarker Programs * Assay Development * Request a Demo * Resources * Points of VUE Blog * Newsroom * Technology Overview * Publications * Posters * Case Studies & Tech Notes * Webinars * Videos * About * Products * Workflow * Panels * Image Analysis * Services & Programs * Staining & Image Analysis * Biomarker Programs * Assay Development * Request a Demo * Resources * Points of VUE Blog * Newsroom * Technology Overview * Publications * Posters * Case Studies & Tech Notes * Webinars * Videos * About Contact Us GETTING TIME ON YOUR SIDE. TURNING COLORFUL INSIGHT INTO MEANINGFUL IMPACT. REQUEST A DEMO REVEALING ACTIONABLE BIOLOGY WITH MULTIPLEX IMMUNOFLUORESCENCE Ultivue seeks to make the promise of immuno-therapy a reality for every patient through rapid, precision profiling of tumor biology. Multiplexing now gives you the power to visualize several biomarkers at once, enabling researchers to quickly elucidate the complex phenotypes of the tumor immune microenvironment (TiME) and advance research discoveries. Reduce TAT in the lab by developing tailored optimized assays that can be applied to a broad range of cancer types and indications to characterize immune contexture. DEVELOP A CUSTOM ASSAY CD8-labeled IHC CD3, Granzyme B, SOX-10, DAPI Cytotoxic T-cell mediated melanoma tumor cell death. In comparison to the limited information from single stain IHC (Left), Multiplexed Immunofluorescence (mIF) can capture an actionable biological event affording disease insight with spatial resolution. Here T cells demonstrate an immune response by recognizing and preparing to kill neighboring tumor cells: CD3-labeled T cells are seen releasing GrzB near SOX-10 labeled tumor cells. DESIGNED WITH TRANSLATIONAL RESEARCHERS AND PATHOLOGISTS IN MIND. H&E CD8, CD68, PD-L1, PanCK, DAPI Co-registered stacked image of mIF Whole Slide Scan ROI PATHOLOGISTS Streamlined workflow Whole-slide imaging Non-disruptive staining Same slide H&E compatible RESEARCHERS Rapid assay development Fully customizable biomarkers Uncover complex phenotypes Advanced image analysis VIEW BIOMARKER MENU DON’T GO IT ALONE: LEVERAGING PARTNERSHIPS Ultivue and its valued partners have established a seamless workflow integrating validated antibodies, state of the art chemistry and advanced analytics to drive personalized medicine. With Ultivue, you know you’re getting the industry’s best at every step. ANTIBODIES Abcam Bethyl Cell Signaling Thermo Fisher STAINERS Leica SCANNERS Olympus Leica Zeiss ANALYSIS Indica Labs VisioPharm CRO'S Indivumed OracleBio Targos SEND US YOUR SAMPLE, WE’LL STAIN AND ANALYZE IT FOR YOU. VUEfinder Gallery ‹› See for yourself SCHEDULE A PILOT TODAY ULTIVUE IS MAKING AN IMPACT Check out our catalogue of peer-reviewed publications and scientific presentations PUBLICATIONS COMPARISON OF A NOVEL MULTIPLEXED IF AND CIHC ADDRESSING IMMUNE STATUS IN NSCLC Read more KAISO: THE LINK BETWEEN AUTOPHAGY, THE TME, AND BREAST CANCER SURVIVAL -Nat. Commun. Biology 2021 Read more A PHASE 1B CLINICAL TRIAL FOR PATIENTS WITH ADVANCED SOLID TUMORS Read more SEE ALL PUBLICATIONS POSTERS CHARACTERIZING SPATIAL DISTRIBUTION OF IMMUNE-CELL SUBSETS IN NONALCOHOLIC STEATOHEPATITIS AND PRIMARY SCLEROSING CHOLANGITIS USING A NOVEL 12-PLEX ULTIMAPPER® KIT Read more ENABLING ACCURATE CELLULAR PHENOTYPING USING THE INSITUPLEX TECHNOLOGY TECHNOLOGY WITH FAST WHOLE-SLIDE SCANNING USING ZEISS AXIOSCAN.Z1 Read more OPTIMIZED MIF USING ULTIMAPPER REAGENTS WITH THE ZEISS AXIOSCAN 7 SCANNER Read more SEE ALL POSTERS WEBINARS ADVANCED PHENOTYPING OF THE TUMOR IMMUNE MICROENVIRONMENT Read more USING MULTIPLEXED IMMUNOFLUORESCENCE FOR SPATIAL QUANTIFICATION OF IMMUNE CELLS Read more COMBINATORIAL IMMUNOTHERAPY WITH ADVANCED SOLID TUMORS Read more SEE ALL WEBINARS STAY CONNECTED BE THE FIRST TO KNOW ABOUT ANY NEW PRODUCT AND SERVICE INFORMATION, NEW PUBLICATIONS AND UPCOMING WEBINAR EVENTS! * Your email address* SUPPORT Contact Us PRODUCTS * Workflow * Panels * Image Analysis SERVICES * Staining & Image Analysis * Biomarker Programs RESOURCES * Points of VUE Blog * Newsroom * Technology Overview * Publications * Posters * Case Studies & Tech Notes * Webinars * Videos COMPANY * Careers * Leadership * Partnerships * Newsroom * Events SUPPORT Contact Us * * 2021 Ultivue, Inc. All rights reserved. For Research Use Only, not for use in diagnostic procedures 763D Concord Avenue, Cambridge MA 02138 * Privacy | * Terms & Conditions * * 763D Concord Avenue, Cambridge MA 02138 2021 Ultivue, Inc. All rights reserved. For Research Use Only, not for use in diagnostic procedures Contact Us * * InSituPlex multiplex immunofluorescence for Chron's Disease and Ulcerative Colitis × Novel 8-plex immunofluorescence within the TME × Using multiplexed immunofluorescence for spatial quantification of immune cells × Multiplex IF for monitoring T-cell exhaustion in IBD and colorectal cancer × InSituPlex technology to support discovery of immune cell signatures in the TME × Developing a multiplex immunofluorescence assay for in depth tumor analysis × Step by step overview of the entire UltiMapper assay × InSituPlex technology for multiplex immunofluorescence × Enabling accurate cellular phenotyping using the InSituPlex technology technology with fast whole-slide scanning using ZEISS Axioscan.Z1 × How InSituPlex technology enables comprehensive high plex immunofluorescence staining of the TME × Characterizing spatial distribution of immune-cell subsets in Nonalcoholic Steatohepatitis and Primary Sclerosing Cholangitis using a novel 12-plex Ultimapper ® kit × Multiplex digital phenotyping across multiple tumor types × Gene expression profiling, digital spatial profiling and multiplex IF in HNSCC tumors × InSituPlex technology for deep phenotypic profiling of the TME × Sequential same slide IF and H&E for phenotypic and morphologic analysis × Comparing CD8 and PD-L1 expression in NSCLC using IF and a brightfield test × The value of same-slide multiplex IF and H&E staining × InSituPlex technology and tissue phenomics to monitor tumor immunity × Phase 1 clinical trial for melanoma patients × Comprehensive I/O profiling in NSCLC × A multiplex assay to assess CD8 activation and tumor co-localization in FFPE tissues × High-multiplex staining with InSituPlex technology × Efficient visualization of multiple cell phenotypes in FFPE tissue sections × A streamlined workflow of InSituPlex technology and the ZEISS Axioscan 7 × Enabling whole slide imaging of a high-plex mIF and cH&E for comprehensive tissue immunophenotyping analysis × Why InSituPlex chemistry is well-positioned by providing unparalleled insight into diseased tissues × Advanced phenotyping of the tumor immune microenvironment × Combinatorial immunotherapy with advanced solid tumors × Multiplex fluorescence IHC with Ultivue InSituPlex × Phenotyping the TME with tissue-based multiplexing assays × Next generation multiplex fluorescence IHC × Investigating targeted T-cell activation × Multiplexing and image analysis of PD-L1 × 8-plex immunofluorescence staining in the TME × Multiplex IF in the TME with customizable InSituPlex assays × Moving from single marker IHC to multiplex IF × Same slide mIF and H&E staining for combined phenotypic and morphological characterization of tumor tissues × Whole-slide acquisition and co-registration of multiplex immunofluorescence tissue images using Immuno-8™ × Optimized mIF using UltiMapper reagents with the ZEISS Axioscan 7 scanner × KEITH WHARTON VICE PRESIDENT, MEDICAL DIRECTOR Keith is a board-certified human anatomic pathologist with diverse achievements in research, drug/diagnostic development, and clinical investigation. Leading Ultivue’s Pathology and Biomarker Analytics team, he brings expertise in investigative pathology, multiplex microscopy and imaging, and digital pathology to our customers striving to realize the promise of personalized medicine. Most recently he was Senior Medical Director of Leica Biosystems, and prior to that he led and supported R&D, toxicology, biomarker, and clinical study teams in multiple therapeutic areas at Biogen and Novartis Institutes for BioMedical Research. He earned a BS in Chemical Engineering from the University of Arizona, and MD and PhD in Molecular Biology from UCLA, where he discovered the molecular basis of DNA recognition by bHLH-PAS transcription factors. Following internship and residency in Anatomic Pathology and fellowships in Autopsy Pathology and Developmental Biology at Stanford, his research lab at UT Southwestern established the Naked cuticle (Nkd) gene family as critical feedback regulators of Wnt/-catenin signaling. × RICHARD C. MALABRE CHIEF FINANCIAL OFFICER Richard is an experienced financial manager with more than thirty years of experience in finance, accounting, internal audit, financial planning and treasury roles. Richard was most recently the Vice President & Controller at Oxford Immunotec Global PLC where he was responsible for the global accounting, finance and treasury functions during their initial public offering, three acquisitions, a divestiture and sale of the company. Prior to Oxford Immunotec, he held Controller and other senior financial roles at several Medical Device and High Technology firms including Salient Surgical Technologies, Neurometrix and Teradyne. Richard earned his BA in Economics from Trinity College, Hartford CT and his Master of Science in Management from MIT’s Sloan School of Management. He is a licensed Certified Public Accountant and a US Navy veteran. × SIOBHAN DESMOND VICE PRESIDENT, HEAD OF PEOPLE AND CULTURE Siobhan Desmond joined Ultivue in early 2021 as Head of People and Culture. Siobhan is responsible for leading the vision and development of the Human Resources strategy, including Talent Acquisition, Total Rewards, Leadership Development, Diversity and Engagement & Inclusion. Siobhan is a business-focused, results oriented executive with over 20 years of experience in diverse industries. She is a leader who invests in designing & implementing successful HR strategies to create thriving, scalable cultures. Siobhan holds a Master of Science in Human Resources and Adult Organizational Learning from Suffolk University as well as a Bachelor of Arts in English from Saint Anselm College. She has advised on boards, such as Veritas Community School and is passionate about life long learning. × MIKE SISMOUR VICE PRESIDENT OF RESEARCH Mike is a chemist/biologist with 15 years experience enabling innovative solutions in the biotechnology and diagnostics industries. He brings extensive experience in nucleic acid chemistry/enzymology, in situ biomolecule detection, multiplexed biomolecule analysis, and sequencing system development. Most recently he was Chief Scientist/Head of Genomics R&D at Beckman Coulter Life Sciences and previously consulted in varying capacities for both established and startup biotechnology companies. Mike earned a BS in Microbiology and Cell Science and a PhD in Nucleic Acid Chemistry from the University of Florida, where he developed artificial genetic systems capable of replication and evolution. He was a NIH Ruth L. Kirschstein Postdoctoral Fellow at Harvard Medical School and a fellow at the Wyss Institute at Harvard where he developed multiplexed sequencing, in situ sequencing, and multiplexed synthetic biology technologies. × BARRY LYNCH VICE PRESIDENT, GLOBAL SALES AND FIELD SUPPORT Barry Lynch has been Vice President of Sales since September 2020. He has significant leadership experience across a broad range of life science businesses, including histology, proteomics and diagnostics. Prior to joining Ultivue he was the Commercial Director (EMEA) with Advanced Cell Diagnostics. Barry began his career with Invitrogen in 1999 where he went on to lead commercial teams at the Europe and Asia Pacific regional level. He holds and honors degree in Biochemistry from the University of Dundee and a MSc in Biotechnology. × MARK REES, PHD VICE PRESIDENT, CORPORATE DEVELOPMENT Mark Rees, PhD joined Ultivue’s executive team in January as Vice President of Corporate Development. Mark has 21+ years of leadership experience in Scientific Affairs and Business development within research and diagnostic markets. Most recently, Mark was instrumental in creating a diagnostic division for StatLab, launching a full portfolio of IHC reagents, automated staining platform as well as a patented reference standard control technology for tissue pathology. Previously Mark held leadership roles in commercial development, Scientific Affairs and R&D at Enzo Lifesciences, Leica Biosystems NA (Danaher) and Novocastra Laboratories. He holds a PhD in Molecular Biology & Microbiology, MS in Industrial Microbiology and a BS (hons) in Biochemistry, graduating from Newcastle University Medical School, England UK × SHARON KEDAR Sharon is Co-Founder, Partner of Northpond Ventures. Sharon is currently a board director at 908 Devices, Emulate, Isoplexis, Ultivue, and Vizgen. She was previously CFO of Sands Capital Management. Over her 15 years with Sands Capital, assets under management grew from $1.5 billion to $50 billion. Prior to Sands Capital, Sharon was a consultant at McKinsey & Company. Sharon has an MBA from Harvard Business School and a BA in Economics from Rice University. She is a CFA charterholder. Sharon is an advocate for financial literacy and her work has been featured nationally, including her two books, ON MY OWN TWO FEET: A Modern Girl’s Guide to Personal Finance and GET FINANCIALLY NAKED: How to Talk Money with your Honey. × ANNA PEVZNER SR DIRECTOR OF FINANCE, CONTROLLER Anna Pevzner is a Controller and Senior Director of Financial Planning & Analysis at Ultivue. Anna has nearly 20 years of finance experience in various positions across life sciences, technology, and advanced materials industries in public and venture capital-backed companies. Most recently Anna led finance function at Veloxint, where she supported fundraising and oversaw planning and accounting for the MIT-incubated advanced materials startup. Prior to Veloxint Anna was a Director of Financial Planning & Analysis at Syneos Health. Earlier in her career she held positions of increasing responsibility, including financial planning and analysis, manufacturing finance and accounting at Dolby Laboratories, Thermo Fisher Scientific and Pelephone Communications. Anna holds an MBA degree from Carnegie Mellon University, Tepper School of Business and BA degree in Economics from Ben-Gurion University of the Negev. × Notifications